GRAD-COV2
GRAD-COV2 has been studied in 1 paper since 2021: 1 trial in people. The newest paper, Oct 27, 2021: “GRAd-COV2, a gorilla adenovirus-based candidate vaccine against COVID-19, is safe and immunogenic in younger and older adults”.
1 paper studies it3 findingsUpdated
At a glance
The findings reach people, from one lab or study. 1 lab in 1 country.
“seroconversion to spike protein and receptor binding domain was achieved in 43 of 44 young volunteers and in 45 of 45 older participants”
None of its findings points the other way.
- 1 lab in 1 country
- Funders: Agence Nationale de la Recherche and 2 more
- Human trial1
Studies in people
1 study gave GRAD-COV2 to people and measured what changed.
| What changed | Design | People | Source |
|---|---|---|---|
up: Induces seroconversion43 of 44 young and 45 of 45 older participants up: Induces neutralizing antibodies42 of 44 younger-age and 45 of 45 older-age volunteers up: Induces T cell response89 of 90 participants | Trialfour weeks | 90 people18 to 85 years oldOlder adults | Science translational medicine, Oct 27, 2021 |
What did studies of GRAD-COV2 find?
3Studies of GRAD-COV2 measured 3 outcomes: T cell response, neutralizing antibodies and seroconversion.
T cell response
upin humans1
1 study
T cell response
upin humans1
GRAD-COV2 induces T cell response in humans (89 of 90 participants).
“GRAd-COV2 induced a robust and T helper 1 cell (TH1)–skewed T cell response against the spike protein in 89 of 90 participants from both age groups”
Human trialthree escalating dosesfour weeksn = 90
Science translational medicine
Neutralizing antibodies
upin humans1
1 study
Neutralizing antibodies
upin humans1
GRAD-COV2 induces neutralizing antibodies in humans (42 of 44 younger-age and 45 of 45 older-age volunteers).
“neutralizing antibodies were detected in 42 of 44 younger-age and 45 of 45 older-age volunteers”
Human trialthree escalating dosesfour weeksn = 90
Science translational medicine
Seroconversion
upin humans1
1 study
Seroconversion
upin humans1
GRAD-COV2 induces seroconversion in humans (43 of 44 young and 45 of 45 older participants).
“seroconversion to spike protein and receptor binding domain was achieved in 43 of 44 young volunteers and in 45 of 45 older participants”
Human trialthree escalating dosesfour weeksn = 90
Science translational medicine